140 related articles for article (PubMed ID: 7625118)
1. HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. The NIAID AIDS Vaccine Clinical Trials Network.
Gorse GJ; Rogers JH; Perry JE; Newman FK; Frey SE; Patel GB; Belshe RB
Vaccine; 1995 Feb; 13(2):209-14. PubMed ID: 7625118
[TBL] [Abstract][Full Text] [Related]
2. Antibody to human immunodeficiency virus type 1 (HIV-1) gp160 in mucosal specimens of asymptomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 IIIB gp160 vaccine. The National Institute of Allergy and Infectious Diseases-sponsored AIDS Vaccine Evaluation Group.
Lambert JS; Viscidi R; Walker MC; Clayman B; Winget M; Wolff M; Schwartz DH
Clin Diagn Lab Immunol; 1997 May; 4(3):302-8. PubMed ID: 9144368
[TBL] [Abstract][Full Text] [Related]
3. Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. NIAID AIDS Vaccine Clinical Trials Network.
Gorse GJ; Frey SE; Patel G; Newman FK; Belshe RB
Vaccine; 1994 Aug; 12(10):912-8. PubMed ID: 7975833
[TBL] [Abstract][Full Text] [Related]
4. Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. The AIDS Vaccine Clinical Trials Network.
Gorse GJ; Frey SE; Newman FK; Belshe RB
J Clin Microbiol; 1992 Oct; 30(10):2606-12. PubMed ID: 1400960
[TBL] [Abstract][Full Text] [Related]
5. Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network.
Montefiori DC; Graham BS; Kliks S; Wright PF
J Clin Immunol; 1992 Nov; 12(6):429-39. PubMed ID: 1287035
[TBL] [Abstract][Full Text] [Related]
6. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
Viscidi R; Ellerbeck E; Garrison L; Midthun K; Clements ML; Clayman B; Fernie B; Smith G
AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607
[TBL] [Abstract][Full Text] [Related]
7. Envelope-specific antibodies in the saliva of individuals vaccinated with recombinant HIV-1 gp160.
Vasudevachari MB; Uffelman KW; Kovacs J; Yeh CK; Lane HC; Salzman NP
J Acquir Immune Defic Syndr (1988); 1992; 5(8):817-21. PubMed ID: 1517967
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network.
Belshe RB; Clements ML; Dolin R; Graham BS; McElrath J; Gorse GJ; Schwartz D; Keefer MC; Wright P; Corey L
J Infect Dis; 1993 Dec; 168(6):1387-95. PubMed ID: 8245523
[TBL] [Abstract][Full Text] [Related]
9. Salivary antibodies to human immunodeficiency virus type 1 in a phase I AIDS vaccine trial.
Archibald DW; Hebert CA; Sun D; Tacket CO
J Acquir Immune Defic Syndr (1988); 1990; 3(10):954-8. PubMed ID: 2204698
[TBL] [Abstract][Full Text] [Related]
10. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a vaccinia-derived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees.
Barrett N; Eder G; Dorner F
Biotechnol Ther; 1991; 2(1-2):91-106. PubMed ID: 1845126
[TBL] [Abstract][Full Text] [Related]
12. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.
Kovacs JA; Vasudevachari MB; Easter M; Davey RT; Falloon J; Polis MA; Metcalf JA; Salzman N; Baseler M; Smith GE
J Clin Invest; 1993 Aug; 92(2):919-28. PubMed ID: 7688766
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network.
Gorse GJ; Schwartz DH; Graham BS; Matthews TJ; Stablein DM; Frey SE; Belshe RB; Clements ML; Wright PF; Eibl M
Clin Exp Immunol; 1994 Nov; 98(2):178-84. PubMed ID: 7955519
[TBL] [Abstract][Full Text] [Related]
14. Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. NIAID AIDS Vaccine Clinical Trials Network.
Gorse GJ; Patel GB; Newman FK; Mandava M; Belshe RB
Vaccine; 1995 Sep; 13(13):1170-9. PubMed ID: 8578800
[TBL] [Abstract][Full Text] [Related]
15. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
Graham BS; Matthews TJ; Belshe RB; Clements ML; Dolin R; Wright PF; Gorse GJ; Schwartz DH; Keefer MC; Bolognesi DP
J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059
[TBL] [Abstract][Full Text] [Related]
16. Antibodies to recombinant gp160 in mucosal secretions and sera of persons infected with HIV-1 and seronegative vaccine recipients.
Funkhouser A; Clements ML; Slome S; Clayman B; Viscidi R
AIDS Res Hum Retroviruses; 1993 Jul; 9(7):627-32. PubMed ID: 8369168
[TBL] [Abstract][Full Text] [Related]
17. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
Gorse GJ; Corey L; Patel GB; Mandava M; Hsieh RH; Matthews TJ; Walker MC; McElrath MJ; Berman PW; Eibl MM; Belshe RB
AIDS Res Hum Retroviruses; 1999 Jan; 15(2):115-32. PubMed ID: 10029244
[TBL] [Abstract][Full Text] [Related]
18. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.
Keefer MC; Graham BS; Belshe RB; Schwartz D; Corey L; Bolognesi DP; Stablein DM; Montefiori DC; McElrath MJ; Clements ML
AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1713-23. PubMed ID: 7888231
[TBL] [Abstract][Full Text] [Related]
19. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.
Mosier DE; Gulizia RJ; MacIsaac PD; Corey L; Greenberg PD
Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2443-7. PubMed ID: 8460155
[TBL] [Abstract][Full Text] [Related]
20. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network.
Dolin R; Graham BS; Greenberg SB; Tacket CO; Belshe RB; Midthun K; Clements ML; Gorse GJ; Horgan BW; Atmar RL
Ann Intern Med; 1991 Jan; 114(2):119-27. PubMed ID: 1984386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
